Skip to content

Isomorphic Labs Raises $5 Billion Series C, Co-Led by Greenoaks and Sequoia Capital

TAT
Traders Agency TeamThe Traders Agency editorial team delivers daily market anal...
November 17, 2026|4 min read
A glowing, crystalline molecular structure suspended in blue light above an empty laboratory bench, with a dim city skyline visible through large windows at dusk.

Follow Traders Agency on Google. Add us as a preferred source so our market analysis shows up more in your Search and AI results.

Add to Preferred Sources

Isomorphic Labs, the London-based AI drug discovery company founded by Sir Demis Hassabis, has raised a $5 billion Series C financing round, according to CNBC and a company announcement distributed via PR Newswire. The round was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and continued investment from Alphabet, Google's parent company, the company said.

Who Backed the Round

According to Isomorphic Labs' statement, the Series C was oversubscribed. Alongside Greenoaks, Sequoia Capital and Andreessen Horowitz, the company said all of its existing investors also participated, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The company's release did not disclose how much each investor contributed or the round's resulting valuation, and neither figure is confirmed in the available reporting.

What the Company Says the Money Will Fund

In the company's announcement, Hassabis said the new capital will let Isomorphic Labs accelerate work on "building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients." Isomorphic Labs said proceeds will go toward maturing its proprietary drug design engine, known as IsoDDE, expanding into new areas of biology, building a partner ecosystem, and constructing what it describes as "scalable AI-first translational and clinical development infrastructure" as it moves drug candidates toward clinical trials.

The company said IsoDDE is already producing "positive preclinical results" in internal oncology and immunology programs as well as partnered programs, which it characterized as "setting the stage for clinical entry." Isomorphic Labs did not provide a specific timeline for when any candidate might enter human trials, and no such date is confirmed in the available reporting.

Greenoaks founder Neil Mehta, quoted in the company's release, framed the investment thesis around the scale of the underlying scientific problem: "Discovering and developing new medicines is an optimization challenge of almost infinite scale. Isomorphic is transforming that journey, building deep learning systems that can predict complex biological behaviors with remarkable accuracy and systematically map the path to new medicines."

Isomorphic Labs is led by CEO Hassabis and President Max Jaderberg. The company is headquartered in London and maintains offices in Cambridge, Massachusetts, and Lausanne, Switzerland, according to its announcement.

Context: A Founder's Pivot and a Sector in Overdrive

CNBC reported that the raise comes roughly three-and-a-half months after Hassabis stepped back as CEO of Google DeepMind, the AI lab he co-founded before Google acquired it in 2014. Hassabis has served as CEO of Isomorphic Labs since it spun out of DeepMind in 2021.

CNBC also reported that drug discovery startups raised a record $23.2 billion in 2026, according to deal-tracking platform Dealroom, and noted that other major AI developers, including OpenAI and Anthropic, have moved into the space. Per CNBC's reporting, Anthropic launched an AI drug discovery program in June and OpenAI partnered with Novo Nordisk in April.

Using Dealroom's figure as reported by CNBC, Isomorphic Labs' $5 billion round represents roughly 21.6% of the sector's 2026 total funding (our calculation: $5 billion divided by $23.2 billion). That math illustrates the scale of a single round relative to a record year for the category, though it is a simple share-of-total calculation rather than an indicator of market share, pipeline progress or company valuation.

Taken together, the reporting suggests investor appetite for AI-driven drug discovery platforms is intensifying at the same time several prominent AI labs, not just Isomorphic Labs, are competing to apply large models to biology and medicine. Whether that capital translates into clinical-stage candidates on any particular timeline is not something the available evidence addresses, and readers should treat the company's own characterization of its preclinical progress as a stated aim rather than a confirmed regulatory or clinical milestone.

Bottom Line

Isomorphic Labs has closed an oversubscribed $5 billion Series C co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz, Alphabet and a roster of existing backers participating. The company says the funds will mature its AI drug-design engine and build out clinical development infrastructure as it works toward its first therapeutic programs entering trials, but it has not disclosed a valuation, investor allocation percentages or a clinical trial start date.

DISCLAIMER: Traders Agency does not offer financial advice. The information provided is for educational purposes only and should not be considered financial advice. Traders Agency is not responsible for any financial losses or consequences resulting from the use of the information provided. Trading carries inherent risks and may not be suitable for all individuals. You are advised to conduct your own research and seek personalized advice before making any investment decisions, recognizing the potential risks and rewards involved.

See more from Traders Agency on Google

Make us a preferred source and our market analysis will appear more prominently in your Google Search, Top Stories, and AI results.

Add to Preferred Sources
Traders Agency

Written by

Traders Agency TeamEditorial Team

The Traders Agency editorial team delivers daily market analysis, stock research, and trading education. Our team of analysts covers stocks, options, crypto, commodities, and macroeconomics to help traders make informed decisions.

Join the Edge

Stop watching.
Start winning.

50,000+ traders get our daily brief before the market opens.

Free. No spam. Unsubscribe anytime.

Traders AgencyWhat Customers Say
4.8
1,544